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Purpose: To investigate the efficacy and safety of a newly developed thermo-responsive sol-gel, ABT13107, for reducing the for-
mation of intrauterine adhesions (IUAs) after hysteroscopic surgery.
Materials and Methods: In this multicenter, prospective, randomized trial (Canadian Task Force classification I), 192 women 
scheduled to undergo a hysteroscopic surgery at one of the eight university hospitals in South Korea were randomized into the 
ABT13107 group or the comparator (Hyalobarrier®) group in a 1:1 ratio. During hysteroscopic surgery, ABT13107 or Hyalobarrier® 
was injected to sufficiently cover the entire intrauterine cavity.
Results: The patients returned to their respective sites for safety assessments at postoperative weeks 1 and 4 and for efficacy as-
sessments at postoperative week 4. The post-surgery incidence of IUAs was 23.4% in the ABT13107 group and 25.8% in the com-
parator group; this difference met the criteria for ABT13107 to be considered as not inferior to the comparator. No differences were 
found in the extent of adhesions, types of adhesions, or the cumulative American Fertility Society score between the two treatment 
groups. Most adverse events were mild in severity, and no serious adverse events occurred. 
Conclusion: ABT13107, a new anti-adhesive barrier containing hyaluronic acid, was not inferior to the highly viscous hyaluronic acid 
anti-adhesive barrier, Hyalurobarrier® in IUA formation after hysteroscopic surgery (Clinical trial registration No. NCT 04007211).
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INTRODUCTION
Intrauterine adhesions (IUAs) refer to the scar tissue formed 
in the uterine cavity in thin film-like or thick band-like struc-
tures. IUAs can result in serious complications such as amen-
orrhea, abnormal uterine bleeding, recurrent miscarriages, and 
infertility due to improper embryo implantation. Patients with 
IUAs can also experience abnormal uterine bleeding or amen-
orrhea. IUAs are usually caused by intrauterine trauma or in-
fection, such as traumatic curettage, endometritis, prolonged 
retention of an intrauterine device, or operative hysteroscopy 
using electrocautery.1,2
Many attempts have been made to prevent the formation of 
IUAs after intrauterine surgery, hysteroscopic surgery, and cu-
rettages.3-7 To reduce the adhesion formation process occurring 
immediately after intrauterine surgery, hormonal treatments 
or anti-adhesion barriers have been applied, including me-
chanical devices or chemical agents with anti-inflammatory 
properties, antioxidants, anticoagulants, and fibrinolytics.8-11
Among chemical agents, hyaluronan, a glycosaminoglycan 
with repeated disaccharide units, is the most commonly used. 
As hyaluronic acid is an elastoviscous fluid that degrades rap-
idly, it does not remain in the cavity long enough to maintain 
the mechanical distension effect during the endometrium’s 
healing process after surgery; this is in contrast to mechanical 
interference devices, such as intrauterine balloons.12 
The uterine cavity may vary in size and shape and is sur-
rounded by a muscular layer of interlacing smooth muscle fi-
bers. Therefore, unlike the nasal or ear cavities that are sur-
rounded by bony structures, the uterine cavity usually collapses 
during the postoperative healing process, unless it is mechan-
ically distended. In addition to that, the uterine cavity covered 
with normal endometrium without IUAs is important for the 
basic functions of the uterus, such as menstruation, and con-
ception. Therefore, we need an anti-adhesion barrier specifi-
cally designed for the uterine cavity. In an effort to modify hyal-
uronic acid by increasing its viscosity and decreasing its rate of 
degradation, a crosslinked modification has recently been ad-
opted.1,6,13-15
ABT13107, a new thermo-responsive sol-gel, was devel-
oped to have both the versatility of a liquid and the adhesive-
ness of a viscous gel. ABT13107 was specifically created for use 
in body cavities such as the intrauterine or nasal cavities. It 
was made from non-animal derived hyaluronic acid and syn-
thetic poloxamers, which are known to have an excellent bio-
compatibility and anti-adhesion effects. As far as we know, no 
study has compared the efficacy of ABT13107 in preventing 
IUAs after hysteroscopic surgery. 
The aim of this randomized clinical trial was to compare the 
efficacy and safety of the newly developed thermo-responsive 
sol-gel ABT13107 (Medytox Inc., Ochang, South Korea) with 
those of the highly viscous hyaluronic acid anti-adhesive bar-
rier, Hyalobarrier® Gel Endo (Hyalurobarrier®) (Anika Thera-
peutic Inc., Bedford, MA, USA), in reducing IUA formation af-
ter hysteroscopic surgery.
MATERIALS AND METHODS
Study subjects and study design
This study was designed as a multi-center, double-blind, ran-
domized, parallel, active-controlled pivotal study to assess the 
anti-adhesive effect and safety of ABT13107 for the prevention 
of IUAs after hysteroscopic surgery. Women between 19 and 
70 years of age who were scheduled to undergo a hysteroscopic 
surgery for submucosal myoma, endometrial polyp, IUA, uter-
ine septa, or abnormal uterine bleeding at eight sites in South 
Korea between February 2017 and August 2018 were enrolled 
in this study. Participants were excluded if they had any of the 
following: gynecologic malignancies, uterine cervix stenosis, 
uterovaginal prolapse, pelvic inflammatory disease, or excessive 
uterine bleeding requiring hysterectomy. Subjects with a history 
of hypersensitivity or allergy to any component of the two study 
materials were also excluded.
This study was conducted according to the regulations of 
Korean Good Clinical Practice and the Declaration of Helsinki. 
This study protocol was approved by the Asan Medical Center 
Institutional Review Board (approval No. 2016-1326), and the 
clinical trial was registered (URL: https://www.clinicaltrials.
gov. Unique identifier: NCT04007211). Informed consent was 
obtained from each patient. 
Randomization and blinding
Subjects who satisfied the inclusion criteria and provided writ-
ten informed consent were randomly assigned to either the 
study group (ABT13107) or the comparator group (Hyalobar-
rier®) in a 1:1 ratio using the dynamic allocation method with 
stratification by site and indication for hysteroscopic operation 
(cause of surgery). Allocation to each group was performed in 
the order of enrollment. 
Surgical and study procedures
Subjects were treated in a sterilized environment after confirm-
ing complete hemostasis and removal of the distension media. 
During the procedure, a suction tool with a blunt tip was used 
to prevent additional endometrial injury. A narrow catheter 
was inserted through the cervix to locate the upper third of 
the uterine cavity. Up to 10 mL of either ABT13107 or Hyalo-
barrier® were injected to sufficiently cover the entire intrauter-
ine cavity. 
The subjects returned to their respective sites for safety as-
sessments at postoperative weeks 1 and 4 and for efficacy as-
sessments at postoperative week 4 (Fig. 1). The primary effi-
cacy outcome was measured by the incidence of de novo IUAs 
at week 4. Secondary efficacy outcomes were measured by 
American Fertility Society (AFS) scores for adhesion extent 
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(area), adhesion type, and their cumulative score at week 4 
based on the independent evaluators’ and investigators’ as-
sessments. The incidence of de novo IUAs based on the judg-
ment of the investigator was also included as a secondary effi-
cacy outcome. Any side-effects associated with the application 
of ABT13107 or Hyalobarrier® were the safety outcomes of this 
study. 
The laboratory tests, including hematology, coagulation test-
ing, electrolyte testing, liver function tests, lipid testing, and 
urinalysis were performed at week 0 and week 4 for safety as-
sessment. Adverse events (AEs) were classified as mild, moder-
ate, and severe. The criteria were divided based on the severity 
of symptoms and the need of intervention.
Three gynecology professors capable of assessing adhesion 
formation, extent, and type of adhesion were selected as inde-
pendent evaluators. The independent evaluators assessed the 
adhesions using photographs of the intrauterine cavity taken 
via hysteroscopy at postoperative week 4 according to the AFS 
classification of IUAs (Supplementary Table 1, only online).16 
To maintain blinding, the evaluators were not allowed to dis-
cuss assessment results with the other investigators or the 
study sponsor until completion of all assessments.
Statistical analysis
The optimal sample size for an adequate power to detect sta-
tistical significance was determined by reviewing the available 
literature.13,14,17-20 The average incidence of IUAs was 10% among 
patients who had received anti-adhesion treatments and 44% 
among non-treated patients. Based on this information, the 
non-inferiority margin was set to 17% from half the difference 
of the efficacy results. A total of 192 subjects, taking into account 
a 15% drop-out rate, was determined to be the minimum num-
ber required to determine the non-inferiority of ABT13107 when 
compared to Hyalobarrier®.
All statistical analyses were performed using the StatView 
System® (SAS Institute, Cary, NC, USA). A p-value less than 
0.05 was considered statistically significant. For the primary 
efficacy outcome, a one-sided 97.5% confidence interval (CI) 
was presented for the difference between the study and com-
parator group. If the upper limit of the confidence interval was 
lower than the non-inferiority margin, it was determined that 
the study group was non-inferior to the comparator group. For 










End of study visit









-  Ineligibility due to inclusion/exclusion criteria 
(n=11)





- Withdrawal of consent (n=2) 
 
Comparator group (n=89)
- Absent efficacy assessment (n=3) 
- Withdrawal of consent (n=3) 
- Lost to follow-up (n=1)
Comparator group (n=96)
Fig. 2. Number of patients assessed and enrolled in the clinical trial.
Fig. 1. CONSORT flow diagram of participants.
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continuous variables, the number, mean, standard deviation, 
median, maximum, and minimum were presented; for cate-
gorical variables, frequency and percentage were presented. 
Values were not adjusted for analysis in this study. 
RESULTS
Subject disposition and baseline characteristics
Of the 226 screened patients, 192 (study group: 96; compara-
tor group: 96) were included and randomized in this study. 
After randomized allocation, six patients withdrew from the 
study (study group: 2; comparator group: 4) and three did not 
complete the efficacy assessment (comparator group: 3). In 
all, 192 patients who were administered the study material 
and who had received at least one safety assessment were in-
cluded in the set for safety analysis; 183 patients who complet-
ed the study and received at least one efficacy assessment were 
included in the set for efficacy analysis (Fig. 2). The demo-
graphics and baseline characteristics obtained at screening, in-
cluding age, height, weight, body mass index, and indication 
for operation, did not differ significantly between the treat-
ment groups (Table 1). 
In terms of indications for operation, endometrial polyp 
was the most common indication (57/92 patients, 59.4%), and 
submucosal myoma (28/92 patients, 29.2%), and others (11/92 
patients, 11.4%) were followed. Others were intra-uterine ad-
hesions (6 patients, 6.25% for study group; 7 patients, 7.29% 
for comparator group), dysfunctional uterine bleeding (5 pa-
tients, 5.21% for study group; 1 patient, 1.04% for comparator 
group), and uterine septae (3 patients, 3.13% for comparator 
group). 
If there was a medical history or an operation history, as of 
the time of written informed consent (present illness), then 
the diagnosis name was coded according to the System Organ 
Class (SOC) and Preferred Term (PT) of Medical Dictionary 
for Regulatory Activitie (MedDRA) 20.0. As a result of classifi-
cation according to the SOC, “reproductive system and breast 
disorders” was investigated the most for both study and com-
parator groups. The most common PT terms were, “adeno-
myosis” in 6.25% (6/96 subjects), “endometrial hyperplasia” 
in 4.17% (4/96 subjects), and “uterine polyp” in 4.17% (4/2.96 
subjects) of the study group, and “ovarian cyst” in 8.33% (8/96 
subjects), “cervical polyp” in 5.21% (5/96 subjects), and “uterine 
polyp” in 5.21% (5/96 subjects) of the comparator group.
Efficacy evaluation
The primary outcome–incidence of de novo IUAs post-surgery 
according to the independent evaluators’ assessments–revealed 
the following; from the efficacy set of 183 patients, 24.6% (45 
patients) experienced IUA formation: 23.40% (22/94 patients) 
in the study group and 25.84% (23/89 patients) in the com-
parator group. The difference in the incidence of adhesions 
between the two groups (study group-comparator group) was 
-2.44% (95% CI: -0.15, 0.10), and the upper limit of the 95% CI 








Age (yr) 40.8±9.1 41.2±9.0 0.750*
Height (cm) 160.32±6.02 160.63±5.37 0.711*
Weight (kg) 59.56±9.26 59.28±8.88 0.830*
BMI (kg/m2) 23.25±3.94 23.00±3.43 0.637*
Indication for operation 1.000†
Submucosal myoma 28 (29.2) 28 (29.2)
Endometrial polyp 57 (59.4) 57 (59.4)
Others 11 (11.4) 11 (11.4)
Intra-uterine adhesions 6 (6.25) 7 (7.29) -
Uterine septae 0� 3 (3.13) -
Dysfunctional uterine bleeding 5 (5.21) 1 (1.04) -
BMI, body mass index.
Data are presented as mean±standard deviation or number (%).
*p-value by independent t-test, †p-value by chi-square test.
Table 2. Primary Efficacy Outcome: IUAs at Postoperative Week 4
Variable Study group (n=94) Comparator group (n=89) Difference (95% CI) p value
Independent evaluator-assessed
Incidence of IUAs 23.40 (22) 25.84 (23) -2.44 (-0.15, 1.10) 0.726†
Extent of cavity involved 1.16±0.34 1.18±0.40 -0.02 (-0.20, 0.16) 0.824*
Type of adhesion 1.36±0.45 1.40±0.52 -0.05 (-0.28, 0.19) 0.701*
Cumulative score 2.49±0.62 2.58±0.87 -0.09 (-0.46, 0.27) 0.609*
Investigator-assessed
Incidence of IUAs 19.15 (18) 13.48 (12) 5.67 (-0.05, 0.16) 0.271†
Extent of cavity involved 1.06±0.24 1.58±1.16 -0.53 (-1.27, 0.22) 0.148*
Type of adhesion 1.39±0.50 1.25±0.45 0.14 (-0.23, 0.51) 0.447*
Cumulative score 2.44±0.62 2.83±1.59 -0.39 (-1.42, 0.65) 0.432*
IUAs, intrauterine adhesions.
Data are presented as mean±standard deviation. Incidence of IUAs is presented as the frequency and (number of cases).
*p-value by independent t-test, †p-value by Cochran-Mantel-Haenszel test (adjusted to underlying disease).
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was 10, which satisfied the non-inferiority margin of <17 (Ta-
ble 2, Fig. 3). 
As to the secondary efficacy outcomes assessed by the in-
dependent evaluators and the investigator at postoperative 
week 4, we found no significant difference between the treat-
ment groups in the extent of adhesion, type of adhesion, or the 
cumulative score, verifying the non-inferiority of ABT13107 to 
Hyalobarrier® (Table 2). 
Safety evaluation
AEs after treatment occurred in 25.0% (24/96 patients, 37 events) 
of the study group and 25.0% (24/96 patients, 29 events) of the 
comparator group. Most of the AEs were mild in severity, and 
no severe AEs occurred in either group. Mild AEs were 83.78% 
(31 cases) for the study group and 86.21% (25 cases) for the 
comparator group. Moderate AEs were 16.22% (6 cases) and 
13.79% (4 cases) for the study and comparator group, respec-
tively. There was no significant difference between the two 
groups for the severity of AEs. Adverse device effects (ADEs) oc-
curred in 6.3% (6/96 subjects, 8 events) of the study group and 
3.1% (3/96 subjects, 3 events) of the comparator group, and 
there was no significant difference between the two groups 
(p=0.497) (Table 3). In the study group, increase in serum low 
density lipoprotein (LDL) concentration was the most frequent 
occurring in 2.08% (2/96 subjects, 2 cases) of subjects, followed 
by ‘dysmenorrhea,’ ‘pelvic pain,’ ‘palpitation,’ ‘abdominal pain,’ 
‘chest pain,’ and ‘tendonitis,’ each occurring in 1.04% (1/96 
subjects, 1 case) of subjects. In the comparator group, increase 
in serum LDL concentration, pyrexia, and vaginal infection was 
reported in each 1.04% (1/96 subjects, 1 case) of subjects. Over-
all, the ADEs reported in this clinical trial were classified as ei-
ther expected or not likely to be relevant to the study device, 
and there were no significant findings in either group related 
to the laboratory tests, vital signs, or on physical examination. 
DISCUSSION
This randomized clinical trial revealed no difference in effica-
cy or safety for the prevention of IUAs after hysteroscopic sur-
geries between ABT13107, the newly developed thermo-re-
sponsive sol-gel, and Hyalobarrier®, a composition of highly 
purified auto-cross-linked hyaluronic acid gel.
In the present study, the overall incidence of IUAs was 23.40% 








Treatment emergent AEs 24 (25.0) [37] 24 (25.0) [29] 0.999
Adverse device effects 6 (6.3) [8]† 3 (3.1) [3]‡ 0.497
Severity of AEs 0.785
Total 37 (100.0) 29 (100.0)
Mild 31 (83.78) 25 (86.21)
Moderate 6 (16.22) 4 (13.79)
Severe 0� 0�
AE, adverse event; LDL, low density lipoprotein.
Data are presented as the number, (frequency), and [number of cases].
*p-value by chi-square test, †Increase in serum LDL concentration (2 cases), 
dysmenorrhoea (1 case), pelvic pain (1 case), palpitation (1 case), abdominal 
pain (1 case), chest pain (1 case), and tendonitis (1 case), ‡Increase in serum 
































Fig. 3. The primary efficacy outcomes: intrauterine adhesions (IUAs) between ABT13107 and Hyalobarrier® assessed by independent evaluators at week 4. 
CI, confidence interval.
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in the ABT13107 group and 25.84% in the comparator group. 
The mean cumulative AFS score for IUAs found during the 
follow-up hysteroscopy was 2.49 in the ABT13107 group and 
2.58 in the comparator group at week 4 (as assessed by inde-
pendent evaluators). These AFS scores show that the adhesion 
types were between “filmy” and “filmy and dense”, and the ex-
tent of the cavity involved was between “<1/3” and “1/3 to 2/3” 
for both groups. Although lower than the incidence with no 
use of prophylaxis,21 the incidence of IUAs seemed to be high-
er, whereas the adhesion score was similar to those of previous 
studies using other cross-linked hyaluronic acid treatments.1,14,22 
However, since the indications for the surgeries (dilation and 
curettage for termination, adhesiolysis, or mass excision), as 
well as the patient characteristics differed across studies, the 
efficacy of IUA prevention should be compared only with con-
trols within the same study. For example, the mean age in the 
current study (about 41 years old) was higher than that of oth-
er studies (mainly early 30s); therefore, there were more par-
ticipants who did not have plans for future pregnancies. Con-
sequently, the surgeons may not have been as concerned with 
avoiding damage to the endometrium during these patients’ 
hysteroscopic surgeries. 
In recent years, anti-adhesive gels derived from hyaluronic 
acid have been widely used to prevent IUAs, as they reduce in-
flammation and improve re-epithelialization and wound heal-
ing.23 A hyaluronic acid-based adhesion barrier has been widely 
used for preventing IUA after operative hysteroscopy. Although 
there are controversies, there is a lack of reproducible evidence 
that hyaluronic acid may decrease the incidence and severity 
of postoperative IUAs. A recent meta-analysis revealed that the 
use of cross-linked hyaluronic acid gel after hysteroscopic oper-
ations effectively reduced IUAs24; now, application of a cross-
linked hyaluronic acid after operation is recommended to re-
duce the development of IUAs.25 
ABT13107 is also a hyaluronic-acid-based anti-adhesive bar-
rier with a sol-gel transition property in response to a rise in 
temperature, called the thermo-responsive sol-gel transition, 
and has the unique characteristic of exerting the anti-adhesion 
effect in the uterine cavity. In a liquid state, it can easily be ap-
plied into the cavity and can spread evenly inside uterine cavi-
ties varying in size and shape. Then, the solution becomes a gel 
in response to the body’s temperature. Unlike liquid-type barri-
ers, the gel-state of ABT13107 can remain for longer in the uter-
ine cavity without an immediate push back. That is, the ther-
mo-responsive sol-gel transition provides both the ease of use 
and extension of exposure to the targeted body parts. Although 
the anti-adhesive efficacy of ABT13107 was comparable with 
Hyalobarrier® in the present study, the thermo-responsive sol-
gel could theoretically be a better option for preventing IUAs in 
clinical practice.
This study had several strengths. First, it was a multicenter, 
double-blind, randomized controlled trial investigating the 
efficacy and safety of the newly developed adhesion barrier. 
Second, almost all of the participants completed the study, and 
only a small number were lost to follow-up. Third, we stratified 
the subjects according to the indication for the operation, as 
the risks for developing IUAs after surgery are known to differ 
between myomectomy and polypectomy (3.6% after polypec-
tomy and 31.3% after myomectomy).18 This stratification can 
provide a clearer result regarding the efficacy of the two anti-
adhesives. Fourth, blinded, experienced clinicians evaluated 
the existence and severity of the IUAs found during the sec-
ond hysteroscopy. Because visual measurement of an adhe-
sion is inevitably subjective, blinding of this assessment was 
helpful to avoid ascertainment bias. 
However, this study also had some limitations. Firstly, the 
follow-up duration for determining the degree of IUAs was rel-
atively short (4 weeks). However, as entire re-epithelialization 
of the uterine cavity and stromal growth usually begins by day 
5–6 of the menstrual cycle, we considered 4 weeks of follow-
up to be sufficient.26 Secondly, there was a lack of data regard-
ing pregnancy outcomes, changes in menstruation, and other 
symptoms. Finally, clinical heterogenicity may have existed 
regarding operating conditions. The distension media (normal 
saline) was the same at all study sites, but the power of electro-
cautery varied. Formation of adhesions may be associated with 
the location or size of the mass, the surgical procedure, includ-
ing cautery use, the surgeon’s skill, or the type of surgery per-
formed. However, these factors were not considered together in 
previous studies investigating the anti-adhesive effects of vari-
ous methods. 
This was not a placebo-controlled trial, we did not demon-
strate that the incidence of IUAs in the study group was re-
duced compared to that of patients who received only a hystero-
scopic operation without an anti-adhesive barrier. Therefore, to 
determine the best method to reduce IUAs, further well-de-
signed, large-scale, randomized controlled trials are needed.
In conclusion, our findings showed that ABT13107, a new 
anti-adhesive barrier containing hyaluronic acid, was non-in-
ferior to the highly viscous hyaluronic acid anti-adhesive bar-
rier, Hyalurobarrier®, in IUA formation after hysteroscopic sur-
gery. To determine the best method to reduce IUAs, further 
well-designed, large-scale, adequately powered randomized 
controlled trials are needed. 
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